Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 23, 2002. The registrant is a foreign issuer reporting pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document primarily serves to disclose changes in directors' interests rather than providing comprehensive financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. No financial statements or performance metrics are included in this specific report.
Material Changes
The only material change disclosed is an increase in the shareholding of Dr. J.P. Garnier. On December 23, 2002, it was notified that Dr. Garnier increased his interest by 11,654 Ordinary Share ADRs. This increase resulted from the re-investment of accrued interest on his account under the SmithKline Beecham Senior Executive Bonus Investment Plan, which occurred on April 2, 2002. The average price for these shares was $47.45 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, future outlook, risk factors, contingencies, or unusual items. The document is limited to the disclosure of the director's share interest change.
Investor Verification Checklist
- Verify the total shareholding of Dr. J.P. Garnier following the addition of 11,654 ADRs.
- Confirm the terms of the SmithKline Beecham Senior Executive Bonus Investment Plan regarding interest re-investment.
- Review the company's Form 20-F for the full year 2002 to obtain actual financial performance data, as this 6-K does not contain it.